stockrowSkye Bioscience, Inc.
SKYE Healthcare Biotechnology
- EPS
- +38.6%
- Free cash flow
- +34.8%
Quarter to June 2026, against a year earlier
Follow SKYE
Alert me
Skye Bioscience, Inc. (SKYE) EV/Sales
As of 6 November 2026, Skye Bioscience, Inc. (SKYE) trades at a EV/Sales of 3.6×. Over the past ten years it has ranged from −18.1× (April 2025) to 2,139× (January 2015); the current reading is higher than 0% of that period. That is below the Biotechnology industry median of 9.0× and in line with the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AZTR Azitra, Inc. compare | −9.1× |
| CANF Can-Fite Biopharma Ltd compare | −8.7× |
| XBIO Xenetic Biosciences, Inc. compare | −0.3× |
| RVPH Reviva Pharmaceuticals Holdings, Inc. compare | n/m |
| NIKI Niki BioSolutions, Inc. compare | 1.3× |
| SKYE Skye Bioscience, Inc. | 3.6× |
| IMNN Imunon, Inc. compare | 6.2× |
| CDIO Cardio Diagnostics Holdings, Inc. compare | 61.5× |
| ADTX Aditxt, Inc. compare | 73.3× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)